A Comprehensive Overview of Globally Approved JAK Inhibitors.
Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. · 2022
Read A Comprehensive Overview of Globally Approved JAK Inhibitors. by Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9146299.txt.
Introduction
Shawky and co-authors give a comprehensive overview of globally approved JAK inhibitors. JAK enzymes pass cytokine signals into cells through the JAK-STAT pathway. That pathway shapes inflammation, immunity, and some cancers. Blocking JAK enzymes has proved useful against several diseases.
The overview covers eleven approved drugs, from abrocitinib to upadacitinib. For each drug it gives synthesis routes and strength against different kinases. It also covers medical uses, crystal structures, and binding modes in detail. Metabolic paths and breakdown products are shown as well. The data should help chemists design new JAK drugs. Readers get chemical and medical facts on a whole drug family in one place.
Catalog record
| CREATOR | Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 138 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |